Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Feb 2;13(1):e232117.
doi: 10.1136/bcr-2019-232117.

Rifampicin induced shock during re-exposure for treatment of latent tuberculosis

Christopher Francis Harlow  1 , Jamilah Meghji  2   3 , Laura Martin  2 , Timothy Harris  2 , Onn Min Kon  2   4
Affiliations
Case Reports

Rifampicin induced shock during re-exposure for treatment of latent tuberculosis

Christopher Francis Harlow et al. BMJ Case Rep. .

Corrected and republished in

Abstract

We present a case of a young Asian female with rheumatoid arthritis who received latent tuberculosis infection (LTBI) treatment prior to treatment with a biologic agent, and developed shock with resistant hypotension on re-exposure to rifampicin. We discuss the epidemiology, pathophysiology and management of rifampicin induced shock, concluding that clinicians should be aware of this rare, but potential adverse effect, and be aware that adverse reactions to rifampicin are more frequent during re-exposure or longer dosing interval regimes. The evidence for desensitisation following such a reaction is lacking and this approach is not currently recommended. We would suggest close collaboration between specialties prescribing immunosuppression and the tuberculosis team when LTBI treatment is required after a reaction, with patient involvement to discuss the risks and benefits of treatment options.

Keywords: drugs: infectious diseases; drugs: respiratory system; infections; tuberculosis; unwanted effects/adverse reactions.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. NICE guidelines Managing latent tuberculosis. Available: https://pathways.nice.org.uk/pathways/tuberculosis#path=view%3A/pathways... [Accessed 18 Apr 2019].
    1. Rifampicin British National formulary. London: BMJ Group and Pharmaceutical Press, 2019. https://bnf.nice.org.uk/drug/rifampicin.html
    1. Rifampin, Toxnet. Available: https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@rn+@rel...
    1. Brasil MT, Opromolla DV, Marzliak ML, et al. Results of a surveillance system for adverse effects in leprosy's WHO/MDT. Int J Lepr Other Mycobact Dis 1996;64:97–104. - PubMed
    1. Hardman JG, Limbird LE, Gilman AG. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th edn New York: McGraw-Hill, 2001: 1279.

Publication types